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Abstract: In recent years, new drug discovery approaches based on novel pharmacological concepts 
have emerged. Allosteric modulators, for example, target receptors at sites other than the orthosteric 
binding sites and can modulate agonist-mediated activation. Interestingly, allosteric regulation may 
allow a fine-tuned regulation of unbalanced neurotransmitter’ systems, thus providing safe and 
effective treatments for a number of central nervous system diseases. The metabotropic glutamate 
type 5 receptor (mGlu5R) has been shown to possess a druggable allosteric binding domain. 
Accordingly, novel allosteric ligands are being explored in order to finely regulate glutamate 
neurotransmission, especially in the brain. However, before testing the activity of these new ligands 
in the clinic or even in animal disease models, it is common to characterize their ability to bind 
mGlu5Rs in vitro. Here, we have developed a new series of fluorescent ligands that, when used in a 
new NanoBRET-based binding assay, will facilitate screening for novel mGlu5R allosteric 
modulators. 
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1. Introduction 
G protein-coupled receptors (GPCRs) are a superfamily of transmembrane receptors that detect 
and transmit a large array of extracellular signals (i.e., sensory stimuli, hormones, neurotransmitters), 
which allow regulating many different physiological functions (i.e., vision, blood pressure, central 
nervous system activity) [1]. Accordingly, these kinds of receptors represent the main target (~35%) 
of clinically used drugs [2]. Most GPCR-targeting drugs consist of ligands, either agonists or 
antagonists, which bind to the endogenous ligand (orthosteric) binding site. However, in recent 
years, an emerging alternative approach to develop novel drugs consists of searching for allosteric 
ligands, which: i) bind to sites topographically distinct from the orthosteric one, and ii) typically, do 
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not possess intrinsic activity, but only modulate the endogenous ligand-mediated function [3]. There 
exist two kinds of allosteric modulators, positive and negative allosteric modulators (PAM and NAM, 
respectively) [3]. Both PAM and NAM may offer a number of advantages over typical orthosteric 
ligands. For instance, these drugs have the potential for higher receptor subtype selectivity, since the 
allosteric binding pockets present higher sequence diversity compared to their orthosteric 
counterparts, which are more conserved and are thus likely to trigger off-target effects [4,5]. 
However, the main strength of allosteric modulators consists of their inability of activating receptors 
by their own. The activity of these kinds of drugs depends on endogenous ligands-mediated 
signaling, thus they may finely modulate receptors instead of fully activating/blocking them [5]. 
Interestingly, the fine-tuning regulation of receptors may be especially relevant in pathologies in 
which neurotransmission systems are unbalanced. This is the case, for instance, for benzodiazepines, 
which provide a safe (with a high therapeutic index) and effective treatment for anxiety, acting as 
PAMs for the GABAA receptor [6].  
Based on the previous notions, in recent years, a number of receptor subtype-selective allosteric 
ligands have been developed for different neurotransmitters’ receptors [7–10], such as the 
metabotropic glutamate receptors (mGluR), which are involved in numerous central nervous system 
pathologies (i.e., schizophrenia, pain, depression, Parkinson’s disease) [11–13]. Glutamate is the 
major excitatory neurotransmitter within the central nervous system and exerts its effects by 
interacting with two main types of receptors (ionotropic and metabotropic) [14,15]. There are eight 
subtypes of metabotropic receptors, which are divided into three groups (I, II, III) based on their 
homology, G-protein coupling and pharmacological profile [14,15]. Group I, comprising mGlu1R and 
mGlu5R, are coupled to Gq/G11 proteins, and upon stimulation lead to phospholipase C activation, IP3 
accumulation, and Ca2+ release from intracellular stores [15]. These receptors are characterized by a 
large N-terminal domain, termed as the venus-flytrap domain, which contains the endogenous 
ligand-binding site; while the allosteric binding site(s) is located at the transmembrane domain [5]. 
Interestingly, to screen for novel mGlu1R and mGlu5R PAMs or NAMs, radioligands and positron 
emission tomography (PET) ligands have been developed [5]. These kinds of ligands allow 
performing cell-based assays, in which apart from assessing orthosteric agonist modulation, it is 
possible to perform binding competition assays to assess affinity for the allosteric binding site. 
However, both PET and radioligand binding are expensive, time-consuming and/or hazardous 
techniques, thus implementing fluorescence-based tools could be desirable. The main drawback of 
using fluorescent mGlu5R allosteric ligands is related to their high lipophilic nature, which may cause 
adsorption to cell surfaces [15]. To circumvent this drawback, resonance energy transfer (RET) 
techniques can be implemented [16,17].  
Here, we have developed a new approach to screen for mGlu5R allosteric ligands, based on the 
engagement of a BRET process between mGlu5bR labelled with a nanolucifecrase (i.e., NanoLuc) and 
selective fluorescent allosteric ligands. Accordingly, we have designed and synthetized a new series 
of fluorescent mGlu5R NAMs, which may be useful to develop a high-throughput screening for novel 
mGlu5R allosteric ligands. 
2. Results 
2.1. Design and Synthesis of the Fluorescent Ligands 
Boron dipyrromethene (BODIPY) is a fluorescent dye with diverse properties, such as 
photochemical stability, high molar absorptivity, high fluorescence quantum yield, and the fact that 
its fluorescence property can be altered by varying the substitution pattern on the core and the 
flanking pyrroles. Alkyne functionalized BODIPY dyes can be used to fluorescently label an azido 
functionalized ligand in a chemo selective manner employing the copper-catalyzed azide-alkyne 
cycloaddition (CuAAC) reaction [18]. Here, we exploited alkyne functionalized BODIPY (573/607) to 
construct a small set of fluorescent mGlu5R ligands based on MTEP (Figure 1).  
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Figure 1. Schematic design of fluorescent mGlu5R ligands based on BODIPY. 
The mGlu5R carboxylate derivatives were condensed with different spacers containing both an 
amine and azide terminus in the presence of the coupling agent EDC and triethylamine to yield six 
intermediate azides as described previously [19]. The synthesis of the desired fluorescent ligands was 
accomplished by reacting each of these azides with an alkyne-modified BODIPY red dye through 
CuAAC. This afforded a concise series of six mGlu5R fluorescent ligands 4a–f (Figure 2). 
 
Figure 2. Structural design of the mGlu5R fluorescent ligands. Chemical representation of the six 
fluorescent NAMs (4a–f) in which a boron dipyrromethene (BODIPY; shown in red) fluorophore is 
fused with MTEP analogues by different spacers (shown in black). 
The excitation and emission spectra of the fluorescent mGlu5R ligands was determined. All 
ligands exhibited similar excitation and emission wavelengths with comparable spectral separation 
(~40 nm) between them (Figure 3a). Next, we assessed the fluorescence intensity by exciting ligands 
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NanoLuc). We used the same concentration of each ligand (10 µM) and read fluorescence intensity at 
607 nm (the theoretical peak of emission of BODIPY) and 610 nm (the wavelength to be read after the 
BRET process between NanoLuc and the fluorescent ligands), respectively. As shown in Figure 3b, 
ligand 4a exhibited a significantly higher fluorescence emission intensity compared to the other 
ligands. Notably, the high fluorescence emission intensity observed at 610 nm upon 490 nm excitation 
supported the possibility of using 4a in the subsequent nanoBRET binding assay. In addition, we also 
selected 4e to be used in further experiments, based on the fact that it exhibited the second highest 
fluorescence emission intensity at both wavelengths (Figure 3b). 
 
Figure 3. Characterization of the fluorescent properties of conjugates 4a–f. (a) Excitation and emission 
spectra of the mGlu5R fluorescent ligands 4a–f. The excitation/emission wavelength peak for each 
compound is shown in nanometers. (b) Fluorescence emission (arbitrary units, A.U.) at 607 nm or 610 
nm is shown after exciting (573 nm or 490 nm, respectively) the six BODIPY-conjugates (10 µM 
solution in 0.05% DMSO of 4a to 4f depicted as light to dark red columns). This value is related to the 
quantum yield of each fluorophore. 
2.2. Characterization of the NanoBRET Binding Assay 
To set up the nanoBRET binding assay, we first validated the cloning of the mGlu5bRNL construct. 
Using immunoblot analysis, mGlu5bRNL expression was ascertained by the presence of a protein band 
of molecular weight ~150 kDa, corresponding to the sum of mGlu5bR (~130 kDa) and NanoLuc (~19 
kDa) proteins (Figure 4a). Moreover, we ascertained the luminescence of cells expressing the 
mGlu5bRNL, by incubating these with the enzyme’s substrate (coelenterazine 400a, 1 µM). While in 
mock-transfected cells no signal was observed, a robust luminescent signal was obtained in 
mGlu5bRNL upon incubation for 5 min with coelenterazine 400a (Figure 4b). Next, we evaluated 
whether the fluorescent ligands could bind and activate mGlu5bR, a condition sine qua non for using 
them in a nanoBRET binding assay. First, we imaged mGlu5bRSNAP-expressing cells (Figure 4c) 
superfused with the fluorescent ligand 4a. Interestingly, 4a nicely decorated the cell surface, but was 
also present inside the cell after 5 min of incubation (Figure 4d). The fact that the ligand penetrated 
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into the cell, either by diffusion or endocytosis, supported the need for developing the nanoBRET 
binding assay instead of determining fluorescence intensity.  
 
Figure 4. Evaluation of the mGlu5bR constructs and ligand 4a in living cells. (a) Immunoblot detection 
of mGlu5bRNL. Increasing amounts of membrane extracts (10 µg, 30 µg and 50 µg of protein) from 
HEK293T cells transiently transfected with mGlu5bRNL were analyzed by immunoblotting using a 
rabbit anti-mGlu5R antibody (1 µg/mL). Asterisk indicates the expected molecular weight (~150 kDa) 
of mGlu5bRNL. (b) Luminescence detection of mGlu5bRNL. HEK293T cells transiently transfected with 
mGlu5bRNL were incubated with coelenterazine 400a for 5 min and luminescence recorded using a 
CLARIOStar plate reader. (c) The expression of mGlu5bRSNAP was determined by assessing the 
fluorescence obtained after staining cells with the SNAP-Surface 647 substrate. (d) Ligand (4a) 
association to and diffusion in mGlu5bRSNAP expressing cells as assessed by laser scanning confocal 
microscopy. The increase of the fluorescent signal was followed during 5 min. Scale bar: 100 µm. 
Next, we tested whether the fluorescent ligands maintained their ability to allosterically 
modulate agonist-mediated mGlu5R signalling. Accordingly, cells were transfected with the 
mGlu5bRSNAP construct and a NFAT-luciferase reporter plasmid (pGL4-NFAT-RE/luc2p) to indirectly 
determine intracellular Ca2+ accumulation (Figure 5a). In these cells, activation of mGlu5bR via the 
application of the agonist quisqualic acid (100 µM) increased intracellular Ca2+, which enhanced 
NFAT-sensitive expression of the luciferase reporter (Figure 5b). Conversely, intracellular Ca2+ 
accumulation was blocked when cells were co-incubated with quisqualic acid (100 µM) and either 
the prototypic mGlu5R NAM MTEP or ligands 4a and 4e (Figure 5b). It can thus be concluded that 
the fluorescent ligands tested retained the ability to bind and allosterically modulate mGlu5R activity. 
 
Figure 5. Effect of the fluorescent mGlu5R NAMs on intracellular calcium levels in HEK293T cells. (a) 
Schematic representation of the NFAT-luciferase reporter assay in which intracellular calcium levels 
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were determined in the presence of quisqualic acid together with the fluorescent mGlu5R ligands 4a 
and 4e. (b) HEK293T cells transfected with mGlu5bRSNAP were first labelled with a non-permeable 
SNAP substrate (SNAP-Surface 647). Next, cells were incubated with 100 µM of quisqualic acid (Quis) 
alone or in combination with 5 µM of MTEP, 4a or 4e for 6 h at 37 °C. The ratio between the luciferase 
activity (535 nm) and the fluorescence intensity of the receptor (647 nm) was calculated to normalize 
the signal by the number of receptor-expressing cells. Data are the mean ± SEM of three independent 
experiments performed in triplicate. ** p < 0.01, one-way ANOVA followed by Dunnett’s post-hoc 
test. Figure designed using image templates from [20].  
2.3. NanoBRET Binding Assay 
Finally, we performed the nanoBRET binding assay (Figure 6a) by transfecting cells with the 
mGlu5bRNL construct and challenging increasing concentrations of the fluorescent ligands, in the 
presence/absence of the non-labeled MTEP. Interestingly, a binding saturation hyperbola was 
obtained for both 4a (KD = 0.84 ± 0.74 µM and Bmax = 37.3 ± 11.4%) and 4e (KD = 1.4 ± 1.2 µM and Bmax 
= 54.3 ± 18.5%), while in the presence of a saturating concentration of MTEP (10 µM) the binding was 
displaced (Figure 6b). Hence, our results show that, despite the high lipophilic nature of the 
fluorescent ligands, it is possible to engage a BRET process, thus supporting that this nanoBRET 
binding assay is a robust and reliable way to assess mGlu5R allosteric ligand binding. 
 
Figure 6. Determination of the binding affinity of 4a and 4e at mGlu5bR using the nanoBRET assay. 
(a) Illustrative representation of the nanoBRET assay in which a nanoluciferase linked to the N-
terminal part of the mGlu5bR (donor) emits light at 490-10 nm in presence of coelenterazine. The light 
excites the BODIPY attached to the ligand (acceptor), which subsequently emits fluorescence at 650-
80 nm. (b,c) NanoBRET saturation binding curves obtained by challenging mGlu5bRNL expressing 
HEK293T cells with increasing concentrations of 4a (b) or 4e (c) in the absence (black circles) or 
presence (white circles) of 10 µM MTEP for 1 h at 37 °C. The specific binding curve (blue circles), the 
KD and the Bmax is shown for each ligand. The represented data are mean ± SEM of three independent 
experiments each performed in triplicate. Figure designed using image templates from [20]. 
3. Discussion 
In recent years, different mGlu5R allosteric drugs have shown efficacy in preclinical animal 
models of disease (i.e., anxiety, depression, drug abuse) [13]. Indeed, a number of clinical trials have 
been engaged, but, to our knowledge, most studies have failed to translate preclinical findings into 
clinics (for review see [21,22]). However, it is important to note that in most cases (i.e., basimglurant 
in depression), the inconclusive data obtained in clinical trials may be explained by some of the 
intrinsic issues of these kinds of trials, such as the placebo effect or limitations related to the treatment 
duration or to the selection of a single dose [22]. Accordingly, in the next years, designing better 
clinical trials is a major challenge to develop improved mGlu5R allosteric drugs. As there remains a 
high interest in developing these kinds of drugs, novel tools to rapidly characterize allosteric ligands 
are clearly awaited. Here, we have designed, synthesized, and characterized a novel series of 
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fluorescent mGlu5R NAMs, which can be used in a nanoBRET assay to robustly and reliably assess 
mGlu5R allosteric ligand binding. This assay based on RET overcomes some of the drawbacks of other 
typical techniques, such as PET or radioligand binding. For instance, PET ligands can be extremely 
useful to visualize disruptions in glutamate transmission or to select the dose to be used in clinical 
trials, but they are expensive to perform ligand binding competition assays. Similarly, radioligand 
binding assays may provide robust data concerning pharmacological constants, but they are also 
expensive, harmful, time-consuming and difficult to miniaturize [16,23]. Regarding RET-based 
assays, a number of approaches have been implemented to study orthosteric ligand-receptor binding. 
For instance, a FRET-based assay (i.e., Tag-lite binding assay) was successfully and reproducibly 
applied to test novel ligands for different GPCRs, demonstrating its suitability for high-throughput 
screening [23]. Similarly, a new BRET-based assay was recently developed using GPCRs tagged with 
a NanoLuc protein to engage a RET process with fluorescent ligands [17,24]. Interestingly, this assay 
was truly homogenous (without any washing step), since it did not require conjugating a fluorophore 
to the GPCR (as in the Tag-lite assay), and was extremely sensitive, due to the brightness of the 
NanoLuc luciferase [17,24]. In the present work, we took advantage of this observation to investigate 
allosteric ligand binding. Of note, both the non-washing conditions and high sensitivity of the 
nanoBRET binding approach allowed to perform this kind of assay even with highly lipophilic 
fluorescent mGlu5R allosteric ligands. Despite the fact that these molecules were rapidly adsorbed 
and penetrated the plasma membrane, thus accumulating into the cell, it was possible to detect a 
specific signal dependent on mGlu5R ligand binding. In addition, it is noteworthy that the fluorescent 
ligands maintained the ability to interact and modulate agonist-mediated responses, thus it could be 
discarded that the BODIPY dye affects ligand binding. On the other hand, it is important to note that 
we used BODIPY derivatives with excitation/emission peaks at 573/607 nm. The reason for this is that 
NanoLuc exhibits a high emission upon coelenterazine incubation, and this signal overlaps and 
masks specific BRET signals when using dyes with lower excitation/emission wavelengths (data not 
shown). Altogether, our nanoBRET binding assay permitted to robustly assess mGlu5R allosteric 
ligand binding and may be viewed as a useful tool to develop novel mGlu5R allosteric ligands. 
4. Materials and Methods 
4.1. Chemistry 
All reactions described were performed under an N2 atmosphere and at ambient temperature, 
unless stated otherwise. All reagents and solvents were purchased from Sigma-Aldrich (Diegem, 
Belgium), Fisher Scientific (Merelbeke, Belgium), TCI Europe (Zwijndrecht, Belgium) or Apollo 
Scientific (Bredbury, Stockport, UK), and used as received. NMR solvents were acquired from 
Eurisotop (Saint-Aubin, France). ESI-HRMS spectra were measured with a Waters LCT Premier XE 
Mass spectrometer calibrated using leu-enkephalin as an external standard. LC-MS analyses were 
carried out on a Waters AutoPurification System equipped with PDA and ESI-MS detection and 
using a Waters CORTECS C18 Column (4.6 × 100 mm, 2.7µm) and a water/acetonitrile/formic acid 
linear gradient system at a flow rate of 1.44 mL min−1. 
General procedure 1: Copper mediated azide-alkyne cycloaddition. To a solution of the azido-
linker modifies MTEP analogues [19] (1.0 eq.) in dimethylformamide (0.1 M) was added the alkyne-
modified BODIPY-red (1.5 eq.), sodium ascorbate (1.0 eq., 0.5 M), CuSO4 (0.2 eq., 0.05 M), 
triethylamine (3.0 eq.) and a catalytic amount of tris[(1-benzyl-1,2,3-triazol-4-yl)methyl]amine. The 
reaction mixture was stirred overnight at room temperature in the dark under an argon atmosphere. 
The solvent was evaporated under reduced pressure and the residue was partioned between water 
and CH2Cl2. The organic fraction was washed with brine and dried over Na2SO4. The crude 
compound was purified by silica gel chromatography (NH4OH/MeOH/CH2Cl2, 1:5:94 v/v/v) to give 
the final compounds as blue solids. 




Blue solid, 48%. LC-HRMS: tR = 7.99 min (10–100% MeCN, 15 min run), purity 95.4%. HRMS 
(ESI) m/z: calculated for C54H63BF2N8O9S [M + 2H]2+ 524.2244; found 524.2223. Calculated for 




Blue solid, 52%. LC-HRMS: tR = 7.62 min (10–100% MeCN, 15 min run), purity 96.8%. HRMS 
(ESI) m/z: calculated for C51H56BF2N7O7S [M + 2H]2+ 479.7006; found 479.6974. Calculated for 




Blue solid, 46%. LC-HRMS: tR = 9.53 min (10–100% MeCN, 15 min run), purity 85.4%. HRMS 
(ESI) m/z: calculated for C61H77BF2N8O4S [M + 2H]2+ 533.2919; found 533.2914. Calculated for 




Blue solid, 39%. LC-HRMS: tR = 6.86 min (10–100% MeCN, 15 min run), purity 90.8%. HRMS 
(ESI) m/z: calculated for C60H76BF2N9O4S [M + 2H]2+ 533.7895; found 533.7896. Calculated for 




Blue solid, 37%. LC-HRMS: tR = 5.93 min (10–100% MeCN, 15 min run), purity 82.5%. HRMS 
(ESI) m/z: calculated for C56H68BF2N9O4S [M + 2H]2+ 505.7582; found 505.7570. Calculated for 




Blue solid, 45%. LC-HRMS: tR= 7.32 min (10–100% MeCN, 15 min run), purity 81.5 %. HRMS 
(ESI) m/z: calculated for C48H51BF2N8O4S [M + 2H]2+ 442.1902; found 442.1881. Calculated for 
C48H50BF2N8O4S [M + H]+ 883.3731; found 883.3779. 
4.2. Plasmids 
The cDNA encoding the rat mGlu5bR [25] was amplified by PCR using the following primers: 
FmGlu5NL (5′-AAACAGAATTCAGTGAGAGGAGGGTGGTGGCTC-3′) and RmGlu5NL (5′-
AAAGATCTAGATCACAACGATGAAGAACTCTGCG-3′) and cloned into the EcoRI/XbaI sites of 
pNLF1-secN [CMV/Hygro] vector (Promega, Stockholm, Sweden), encoding a fusion of the secretory 
signal peptide sequence of IL-6 on the N terminus of NanoLuc (Nluc). The mGlu5bRNL construct was 
confirmed by sequencing analysis. The resulting open reading frame therefore encoded a fusion of 
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secreted Nluc at the N terminus of mGlu5bR. The mGlu5bRSNAP construct was previously described 
[26]. 
4.3. Cell Culture and Transfection 
Human embryonic kidney (HEK)-293T cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 1 mM sodium pyruvate, 
2 mM L-glutamine, 100 U/mL streptomycin, 100 mg/mL penicillin and 5% (v/v) fetal bovine serum at 
37 °C and in an atmosphere of 5% CO2. HEK-293T cells growing in 60 cm2 plates were transfected 
with the cDNA encoding the different plasmids using linear PolyEthylenImine reagent (PEI) 
(Polysciences Inc., Valley Road Warrington, PA, USA) as previously described [27]. 
4.4. Membrane Preparations and Immunoblotting 
To prepare membranes, cells were homogenized in ice-cold 50 mM Tris-HCl (pH 7.4), 1 mM 
EDTA, 300 mM KCl buffer containing a protease inhibitor cocktail (Roche Molecular Systems, 
Pleasanton, CA, USA) using a Polytron for three periods of 10 s each. The homogenate was 
centrifuged for 10 min at 1000× g at 4 °C. The resulting supernatant was centrifuged for 30 min at 
12,000 × g at 4 °C. Membranes were dispersed in 50 mM Tris HCl (pH 7.4) and 10 mM MgCl2 and 
protein concentration determined using the BCA protein assay kit (Thermo Fisher Scientific, Inc., 
Rockford, IL, USA). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS/PAGE) was 
performed using 10% polyacrylamide gels. Proteins were transferred to Hybond®-LFP 
polyvinylidene difluoride (PVDF) membranes (GE Healthcare, Chicago, IL, USA) using a Trans-Blot® 
SD Semi-Dry Transfer Cell (Bio-Rad, Hercules, CA, USA). PVDF membranes were blocked with 5% 
(wt/vol) dry non-fat milk in PBS containing 0.05% Tween-20 (PBS-T) during 2h and immunoblotted 
using rabbit anti-mGlu5R antibody (1 µg/mL; Millipore, Billerica, MA, USA) in blocking solution 
overnight at 4 °C. PVDF membranes were washed with PBS-T three times (5 min each) before 
incubation with a horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1/30,000; Pierce 
Biotechnology, Rockford, IL, USA) in blocking solution at 20 °C during 2 h. After washing the PVDF 
membranes with PBS-T three times (5 min each) the immunoreactive bands were developed using a 
chemiluminescent detection kit (Thermo Fisher Scientific) and detected with an Amersham Imager 
600 (GE Healthcare). 
4.5. NanoBRET Experiments 
The NanoBRET assay was performed on cells transiently transfected with mGlu5RNL, according 
to [17]. In brief, cells were re-suspended in Hank’s Balanced Salt Solution (HBSS; 137 mM NaCl, 5.4 
mM KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4, 4.2 mM NaHCO3, 
pH 7.4), containing 10 mM glucose, and seeded into poli-ornitine coated white 96-well plates. After 
24 h, cells were challenged with/without the non-labelled mGlu5R NAM (MTEP; Tocris Bioscience; 
Ellisville, MI, USA) and incubated for 1 h at 37 °C. Subsequently, the fluorescent ligand was added 
and the plate returned to 37 °C for 1 h. Finally, coelenterazine 400a (NanoLight Technologies; Pinetop, 
AZ, USA) was added at a final concentration of 1 µM, and readings were performed after 5 min using 
a CLARIOStar plate reader (BMG Labtech; Durham, NC, USA). The donor and acceptor emission 
was measured at 490 ± 10 nm and 650 ± 40 nm, respectively. The raw NanoBRET ratio was calculated 
by dividing the 650 nm emission by the 490 nm emission and the values fitted by non-linear 
regression using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA). In competition studies, 
results were expressed as a percentage of the maximum signal obtained (mBU; miliBRET Units). 
4.6. Intracellular Calcium Determinations 
The mGlu5R-mediated intracellular Ca2+ accumulation was assessed by means of a luciferase 
reporter assay based in the expression of the nuclear factor of activated T-cells (NFAT), as previously 
described [28]. In brief, cells were transfected with the cDNA encoding the mGlu5RSNAP and the 
NFAT-luciferase reporter (pGL4-NFAT-RE/luc2p; Promega). Plasmids were co-transfected by 
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preparing a 1:1 solution (1.5 + 1.5 µg) in NaCl and mixing it with a solution containing 14.5 µg of PEI. 
The final solution was added to the cells plate for 4 h and thereafter replaced with fresh medium. 
After 36 h post-transfection, cells were first labelled with a non-permeable SNAP substrate (SNAP-
Surface 647 ligand; New England BioLabs, Ipswich, MA, USA), as previously described [29]. 
Thereafter, cells were incubated with quisqualic acid in the presence/absence of the different NAMs 
tested for 6h. Subsequently, cells were harvested with passive lysis buffer (Promega) and transferred 
to 96-wells white plates. First, fluorescence was assessed and thereafter the luciferase activity of cell 
extracts was determined using a luciferase Bright-GloTM assay (Promega) according to the 
manufacturer’s protocol. Both fluorescence (647 nm) and luciferase activity (535 nm) were 
determined in a CLARIOStar Optima plate-reader (BMG Labtech). The ratio between 535/647 nm was 
calculated. 
4.7. Imaging 
The localization of the mGlu5R NAMs was evaluated using a live-cell laser scanning confocal 
microscopy. To this end, cells were transfected with mGlu5bRSNAP and, upon 36 h post-transfection, 
seeded into a chamber culture slide (Thermo Fisher Scientific). After 24 h, the medium was replaced 
by HBSS and single cells were examined using a Carl Zeiss LSM 880 spectral confocal laser scanning 
microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) equipped with a multiline argon laser 
(458 nm, 488 nm and 514 nm), 405nm and 561nm diode lasers and 633 nm He/Ne laser (Centres 
Científics i Tecnològics, Universitat de Barcelona, Bellvitge Campus, Barcelona, Spain) using a 63 × 
oil immersion objective (1.4 numerical aperture) an image resolution of 1024 × 1024 pixels. To assess 
association and diffusion of the fluorescent NAM (4a), it was added (5 µM) to the chamber and live-
cell imaging was performed for 5 min. 
4.8. Statistics 
The number of samples (n) in each experimental condition is indicated in figure legends. 
Statistical analysis and significance is indicated for each experiment. 
5. Conclusions 
In summary, we have developed a new series of fluorescent ligands acting as NAMs for the 
mGlu5R. Interestingly, we showed that these ligands bind and modulate the receptor’s activity. In 
addition, as these they are compatible with NanoBRET binding experiments, they may eventually 
evolve into a useful tool for the pharmacological study of mGlu5R both in vitro and in vivo. 
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